Tuberculosis Drugs Market – Insights
Tuberculosis (TB) is a chronic condition, and has become a global disease burden. Manufacturers of TB drugs are focused on developing drugs that can shorten the duration of treatment, and help to overcome challenges of drug-susceptible TB and drug-resistant TB. The treatment of TB is divided into two types, such as first line treatment, second line treatment, and drug resistant treatment.
Advanced technologies and introduction of novel therapies are expected to improve the duration of treating TB, however, most TB cases with currently available medicines can require up to 6 months of treatment. However, despite of existing medicines and ongoing TB treatment drugs innovations, there is continuous need to improve patients’ access to appropriate TB medicines particularly in the areas of multidrug-resistant TB (MDR TB) and pediatric TB.
The global tuberculosis drugs market was valued at US$ 1,146.5 million in 2019, and is expected to exhibit a CAGR of 5.3% over the forecast period (2019 – 2027).
Global Tuberculosis Drugs Market Share (%) Analysis, by Therapy Type, 2019
Source: Coherent Market Insights Analysis (2019)
Increasing R&D Investments and New Drug Developments Are Expected to Drive Growth of the Tuberculosis Drugs Market
Increasing number of drug developments are driving growth of the tuberculosis drugs market. U.S.-based TB Alliance, a nonprofit organization, has developed a new drug for treating highly drug-resistant forms of tuberculosis. For instance, in August 2019, TB Alliance received the U.S. FDA approval for Pretomnid, a combination regimen with bedaquiline and linezolid, which is developed and indicated for the treatment of patients with XDR-TB, or intolerant non-responsive MDR-TB.
Moreover, market players are focusing on strategic collaborations to commercialize their newly developed drugs. For instance, in April 2019, Mylan, a pharmaceuticals company, collaborated with TB Alliance to commercialize the Pretomanid drug for treating pulmonary tuberculosis (TB).
Furthermore, high prevalence of TB across the globe is driving growth of the TB drugs market. For instance, according to WHO’s global tuberculosis report 2018, around 10 million people worldwide suffered from TB in 2017.
Tuberculosis Drugs Market – Restraints
The increasing incidence of drug recall is a major factor restraining the market growth. Manufacturers of TB drug are facing challenges such as increasing product recalls owing to factors such as packaging or manufacturing flaws. For instance, in 2018, Sandoz recalled its batch of wrongly-packed tuberculosis (TB) drugs in India. Furthermore, in 2016, Novartis manufactured a drug Onecure which was recalled by the Philippines Food and Drug Administration for insufficient amount of rifampicin in the drug.
The high pricing of drugs is another factor restraining the growth of the market. Second line treatment drugs are highly priced compared to first line treatment with more side effects and high level toxicity.
Tuberculosis Drugs Market - Regional Insights
On the basis of region, the global tuberculosis drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among region, North America is expected to hold a dominant position in the global tuberculosis drugs market over the forecast period, owing to higher cost of TB drugs in the region. For instance, in 2015, the Cycloserine drug for treating multidrug-resistant tuberculosis, increased its price from US$15 per tablet to US$ 360 per tablet owing to transfer of rights to Rodelis Therapeutics.
The market in Europe is expected to grow over the forecast period, owing to high prevalence of tuberculosis in the region. For instance, according to the TB Europe Coalition, in 2015, about 323,000 new TB cases and 32,000 deaths were reported in Europe.
Global Tuberculosis Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027
Source: Coherent Market Insights Analysis (2019)
Tuberculosis Drugs Market - Competitive Landscape
Major players operating in the global tuberculosis drugs market include Johnson & Johnson Services, LLC, Lupin Ltd, Novartis AG, Macleods Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., and others.
Tuberculosis is a common infectious disease caused by mycobacterium tuberculosis that affects the lungs. The treatment of TB is divided into two types; first line therapy and second line therapy. In first line therapy, TB is treated with drugs such as isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), ethambutol (EMB), and streptomycin (SM). However, first line therapy fails more often in the cases of drug resistant bacterial TB. Tuberculosis is classified into latent tuberculosis and active tuberculosis.
The high burden of TB is driving the growth of this market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30 include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa which accounted for two thirds of the new TB cases.
Increasing global burden of TB is expected to drive the tuberculosis drugs market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.
Moreover, according to WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$12 billion in additional economic costs and lost productivity. Increasing healthcare spending on treatment of TB is expected to drive growth of the market. Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.
Moreover, increasing investments in research and development activities are expected to drive growth of the market. According to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017 with an increase of 6% (or US$ 46 million), compared to US$726 million in 2016.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 28 market data tables and 33 figures on “Tuberculosis Drugs Market” - Global forecast to 2027”
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.